Discuss Melanotan II on glp1chat
Join the forum to discuss research with other members.
At a glance
Melanotan II activates melanocortin receptors. In pigmentation research, this can increase melanin, the pigment that darkens skin; its action at other receptors can also affect the body beyond the skin. Darker skin does not mean protection from sun damage.
Melanocortin receptors are found in more than one part of the body. Activating those involved in skin pigment can increase melanin, but activity at other receptors helps explain effects beyond tanning. Pigment changes are the visible research outcome, not a measure of protection from ultraviolet light. Reports of unwanted effects are part of interpreting this compound, not an unrelated footnote.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Pigmentation findings should be read together with adverse events and case reports. Increased pigmentation is not evidence of protection from ultraviolet damage or skin cancer.[1][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Melanotan II.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Standard / Gradual Titration (3 mL = 3.33 mg/mL)
| Week / Phase | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 250 mcg (0.25 mg) | 7.5 units (0.075 mL) |
| Week 2 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
| Week 3 | 750 mcg (0.75 mg) | 22.5 units (0.225 mL) |
| Weeks 4–8 | 1000 mcg (1 mg) | 30 units (0.30 mL) |
| Maintenance(after Week 8) | 500–1000 mcg(1–2× weekly) | 15–30 units(0.15–0.30 mL) |
Frequency: Inject once daily subcutaneously during the initial 8-week tanning phase; transition to 1–2 injections per week for maintenance dosing to sustain pigmentation[3]. This schedule uses the standard 3.0 mL dilution for consistent unit measurements. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once-daily subcutaneous regimen.
- Goal: Increase skin pigmentation (tanning) through melanocortin receptor activation[1].
- Schedule: Daily subcutaneous injections for 6–8 weeks during loading phase, then maintenance dosing 1–2× weekly[3].
- Dose Range: 250–1000 mcg daily with gradual titration to minimize side effects.
- Reconstitution: 3.0 mL per 10 mg vial (3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 1–2 weeks[6].
Suggested daily titration approach based on clinical research.
- Start: 200–250 mcg daily; increase by 100–250 mcg increments every 1–2 weeks as tolerated[2].
- Target: 500–1000 mcg daily by Weeks 4–8 (studied effective range is 1–2 mg/day)[1].
- Frequency: Once per day (subcutaneous) during loading phase.
- Cycle Length: 6–8 weeks for initial tanning, then switch to maintenance dosing.
- Maintenance: 500–1000 mcg administered 1–2× per week to sustain pigmentation[3].
- Timing: Any consistent time; rotate injection sites to reduce irritation.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to avoid foaming; do not shake vigorously.
- Gently roll or swirl the vial until the powder is fully dissolved.
- Label the vial with the reconstitution date and store refrigerated at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide stability and potency.
- Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; keep desiccated to minimize moisture exposure[6].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1–2 weeks with bacteriostatic water preservative[6].
- Avoid freeze–thaw: Do not refreeze reconstituted solution; prepare aliquots if longer storage needed.
- Allow vials to reach room temperature before opening to reduce condensation.
Injection Technique
Subcutaneous injection guidance from clinical best-practice resources[7][9].
- Clean the vial stopper and injection site with alcohol swabs; allow both to air dry completely[9].
- Use a 1 mL insulin syringe (29–31 gauge, ½ inch needle) for subcutaneous administration[7].
- Pinch a fold of skin approximately 1 inch thick at the injection site (abdomen preferred, at least 2 inches from navel)[8].
- Insert the needle at 45–90° depending on body composition; release the pinch after needle insertion[8].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
- Withdraw the needle at the same angle; apply gentle pressure with clean gauze if needed.
- Rotate sites systematically to avoid lipohypertrophy or scarring[8].
- Dispose of used syringes immediately in a proper sharps container; never reuse needles[7].
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with gradual titration (including transition to maintenance dosing).
-
Peptide Vials (Melanotan II, 10 mg each):
- 8 weeks ≈ 5 vials (~45–50 mg total)
- 12 weeks ≈ 8 vials (~70–75 mg total)
- 16 weeks ≈ 10 vials (~95–100 mg total)
-
Insulin Syringes (U-100, 1 mL):
- Per week (daily dosing): 7 syringes
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- 12 weeks (8 vials): 24 mL → 3 × 10 mL bottles
- 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
PubMed — Dorr RT et al. (1996) — Phase I clinical study of melanotan-II, evaluation of dosing and safety in healthy volunteers (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
PubMed — Nelson ME et al. (2012) — Case report: Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑